Pharmaceutical Technology's Equipment and Machinery Trends Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Equipment and Machinery Trends Survey
The pharmaceutical industry plans moderate increases in spending for equipment and machinery in 2008. Investments include equipment for solid-dosage manufacturing, active pharmaceutical ingredients, and parenteral manufacturing.


Pharmaceutical Technology
Volume 3, Issue 32

Impact factors for 2008 spending

As in 2007, compliance with good manufacturing practices will most influence purchasing decisions in 2008; 58% report this as a high-impact factor for planned spending for 2008. About 37.9% of respondents ranked expansion of manufacturing facilities as a high-impact factor. Nearly 30% ranked adding enhancements, upgrades, and/or technology as a high-impact factor.

As in 2007, QbD and the PAT initiatives are not strong influences on planned spending for 2008. Roughly half (49.4%) of respondents said QbD had either no impact or little impact on their planned purchases for 2008. Even more respondents (58.1%) say that PAT will have little or no impact.

Regional spending

For 2008, there was virtually no change in regional spending habits. Seventy-four percent of respondents plan to spend in the United States (including Puerto Rico) and Canada, and 14% in Western Europe. In 2007, 75% spent in the US and Canada, and 16% in Western Europe.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here